Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Oberst MD, Augé C, Morris C, Kentner S, Mulgrew K, McGlinchey K, Hair J, Hanabuchi S, Du Q, Damschroder M, Feng H, Eck S, Buss N, de Haan L, Pierce AJ, Park H, Sylwester A, Axthelm MK, Picker L, Morris NP, Weinberg A, Hammond SA. Oberst MD, et al. Mol Cancer Ther. 2018 May;17(5):1024-1038. doi: 10.1158/1535-7163.MCT-17-0200. Epub 2018 Mar 15. Mol Cancer Ther. 2018. PMID: 29545330 Free PMC article.
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
Leyland R, Watkins A, Mulgrew KA, Holoweckyj N, Bamber L, Tigue NJ, Offer E, Andrews J, Yan L, Mullins S, Oberst MD, Coates Ulrichsen J, Leinster DA, McGlinchey K, Young L, Morrow M, Hammond SA, Mallinder P, Herath A, Leow CC, Wilkinson RW, Stewart R. Leyland R, et al. Among authors: oberst md. Clin Cancer Res. 2017 Jul 1;23(13):3416-3427. doi: 10.1158/1078-0432.CCR-16-2000. Epub 2017 Jan 9. Clin Cancer Res. 2017. PMID: 28069723
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
Schofield DJ, Percival-Alwyn J, Rytelewski M, Hood J, Rothstein R, Wetzel L, McGlinchey K, Adjei G, Watkins A, Machiesky L, Chen W, Andrews J, Groves M, Morrow M, Stewart RA, Leinster A, Wilkinson RW, Hammond SA, Luheshi N, Dobson C, Oberst M. Schofield DJ, et al. MAbs. 2021 Jan-Dec;13(1):1857100. doi: 10.1080/19420862.2020.1857100. MAbs. 2021. PMID: 33397194 Free PMC article.
MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential.
Tigue NJ, Bamber L, Andrews J, Ireland S, Hair J, Carter E, Sridharan S, Jovanović J, Rees DG, Springall JS, Solier E, Li YM, Chodorge M, Perez-Martinez D, Higazi DR, Oberst M, Kennedy M, Black CM, Yan L, Schwickart M, Maguire S, Cann JA, de Haan L, Young LL, Vaughan T, Wilkinson RW, Stewart R. Tigue NJ, et al. Oncoimmunology. 2017 Feb 3;6(3):e1280645. doi: 10.1080/2162402X.2017.1280645. eCollection 2017. Oncoimmunology. 2017. PMID: 28405505 Free PMC article.
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, Mulgrew K, Oberst MD, Hammond SA, Baeuerle PA, Kufer P. Lutterbuese R, et al. Among authors: oberst md. J Immunother. 2009 May;32(4):341-52. doi: 10.1097/CJI.0b013e31819b7c70. J Immunother. 2009. PMID: 19342971
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.
Pore N, Wu S, Standifer N, Jure-Kunkel M, de Los Reyes M, Shrestha Y, Halpin R, Rothstein R, Mulgrew K, Blackmore S, Martin P, Meekin J 3rd, Griffin M, Bisha I, Proia TA, Miragaia RJ, Herbst R, Gupta A, Abdullah SE, Raja R, Frigault MM, Barrett JC, Dennis PA, Ascierto ML, Oberst MD. Pore N, et al. Among authors: oberst md. Cancer Discov. 2021 Nov;11(11):2828-2845. doi: 10.1158/2159-8290.CD-20-1543. Epub 2021 Jul 6. Cancer Discov. 2021. PMID: 34230008
Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model.
El Meskini R, Atkinson D, Kulaga A, Abdelmaksoud A, Gumprecht M, Pate N, Hayes S, Oberst M, Kaplan IM, Raber P, Van Dyke T, Sharan SK, Hollingsworth R, Day CP, Merlino G, Weaver Ohler Z. El Meskini R, et al. Mol Cancer Res. 2021 Aug;19(8):1422-1436. doi: 10.1158/1541-7786.MCR-20-0881. Epub 2021 Apr 22. Mol Cancer Res. 2021. PMID: 33888600 Free PMC article.
HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells.
Xia L, Wen L, Qin Y, Dobson HE, Zhang T, Comer FI, Hinrichs MJ, Oberst MD, Coats SR, Chang AE, Liu Y, Bao Y, Dai F, Wicha MS, Li Q. Xia L, et al. Among authors: oberst md. Cell Chem Biol. 2021 May 20;28(5):610-624.e5. doi: 10.1016/j.chembiol.2021.02.013. Epub 2021 Mar 11. Cell Chem Biol. 2021. PMID: 33711257 Free PMC article.
34 results